Clinical Trial

Relationship Between Red Cell Distribution Width (RDW) and HbA1C in Patients With Type 2 Diabetes Mellitus After Glycemic Control

Recruiting
View on ClinicalTrials.gov →
Summary
Diabetes mellitus (DM) is an epidemic disease, with approximately 463 million persons diagnosed with it. Of those, 90% are patients with type 2 DM (T2DM). Some estimates indicate that 700 million cases of DM will be reported in 2045. T2DM develops due to insulin resistance, leading to reduced insulin secretion. DM has a number of associated complications, such as nephropathy, neuropathy, and cardiovascular disease.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12-30 -> 2027-12-30 2026-07-31
minor Completion pushed: 2026-06-30 -> 2028-06-30 2026-07-31
Trial Details
NCT Number NCT06067399
Lead Sponsor New Valley University
Conditions Type 2 Diabetes
Enrollment 250 participants
Start Date 2026-05-01
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-30